EP0930891A4 - Oral administration of chicken yolk antibodies to treat disease - Google Patents

Oral administration of chicken yolk antibodies to treat disease

Info

Publication number
EP0930891A4
EP0930891A4 EP97909921A EP97909921A EP0930891A4 EP 0930891 A4 EP0930891 A4 EP 0930891A4 EP 97909921 A EP97909921 A EP 97909921A EP 97909921 A EP97909921 A EP 97909921A EP 0930891 A4 EP0930891 A4 EP 0930891A4
Authority
EP
European Patent Office
Prior art keywords
oral administration
treat disease
yolk antibodies
chicken yolk
chicken
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97909921A
Other languages
German (de)
French (fr)
Other versions
EP0930891A1 (en
Inventor
Marilyn A Coleman
Mitchell V Kaminski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovimmune Inc
Original Assignee
Ovimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovimmune Inc filed Critical Ovimmune Inc
Publication of EP0930891A1 publication Critical patent/EP0930891A1/en
Publication of EP0930891A4 publication Critical patent/EP0930891A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
EP97909921A 1996-10-02 1997-10-02 Oral administration of chicken yolk antibodies to treat disease Withdrawn EP0930891A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72440896A 1996-10-02 1996-10-02
US724408 1996-10-02
PCT/US1997/017722 WO1998014209A1 (en) 1996-10-02 1997-10-02 Oral administration of chicken yolk antibodies to treat disease

Publications (2)

Publication Number Publication Date
EP0930891A1 EP0930891A1 (en) 1999-07-28
EP0930891A4 true EP0930891A4 (en) 2001-07-04

Family

ID=24910322

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97909921A Withdrawn EP0930891A4 (en) 1996-10-02 1997-10-02 Oral administration of chicken yolk antibodies to treat disease

Country Status (7)

Country Link
EP (1) EP0930891A4 (en)
JP (1) JP2001501622A (en)
KR (1) KR20000048855A (en)
AU (1) AU729502B2 (en)
CA (1) CA2267421A1 (en)
NZ (1) NZ335170A (en)
WO (1) WO1998014209A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395273B1 (en) 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
EP1085906B1 (en) * 1998-06-10 2008-08-13 Ophidian Pharmaceuticals, Inc. Anti il6 antibodies in the prevention and treatment of inflammatory bowel disease
US7494652B1 (en) * 1998-06-10 2009-02-24 Promega Corporation Treatment of sepsis
DE19910159A1 (en) * 1999-02-26 2000-09-14 Rosemarie Heis Specific IgY egg yolk antibodies, their extraction and their use
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
CA2395840A1 (en) 1999-12-27 2001-07-05 The University Of Manitoba Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic escherichia coli and other pathogens
KR100364198B1 (en) * 2000-06-09 2002-12-12 영농조합법인다한 An Improved Method for Inducing IgY to Helicobacter pylori and an Egg Prepared by Using the Same
MXPA03006819A (en) * 2001-01-30 2004-10-15 Lauridsen Group Inc Methods and compositions for treatment of immune dysfunction disorders.
MXPA03006818A (en) * 2001-01-30 2004-10-15 Lauridsen Group Inc Methods and compositions for modulating the immune system of animals.
CA2339436A1 (en) * 2001-03-15 2002-09-15 Josee Harel Production of antibodies against virulence factors associated with strains of escherichia coli (aeec), and their use
KR20030026502A (en) * 2001-09-26 2003-04-03 배만종 A production method of common egg, native egg, blue egg have various skill
KR100392566B1 (en) * 2001-11-13 2003-07-23 주식회사 에그 바이오택 THE PRODUCTION METHOD OF EGG CONTAINING MIXING IgY ABOUT Propionibacterium acnes, Staphylococcus epidermidis, E.coli CAUSING ACNES AND THEREOF PREVENTING COSMETICS FOR ACNES SKIN CONTAINING MIXING IgY
EP1476184A4 (en) * 2001-12-28 2006-01-04 Camas Inc Immunogen adherence and method of making and using same
KR100489615B1 (en) * 2002-01-30 2005-05-17 주식회사 단바이오텍 Antibody For Prevention And Treatment Of Listeria Monocytogenes Infection, Eggs Containing Thereof And Method For Producing Thereof
KR20030079382A (en) * 2002-04-04 2003-10-10 최태부 An antibody induced by digestive enzyme-fatty acid complex and use thereof
AU2002313212A1 (en) * 2002-06-13 2003-12-31 Kabushiki Gaisha Tokaibiken Tailor-made preparation and process for producing the same
KR20040005539A (en) * 2002-07-10 2004-01-16 백반석 The method for separation and production of water-soluble specific protein(IgY) using electrolytic water and saccharide
KR20040005541A (en) * 2002-07-10 2004-01-16 선우선영 The effective producing method of anti-acnes IgYs in several form.
KR20040005540A (en) * 2002-07-10 2004-01-16 백반석 The method for production of specific yolk antibody containing anti-helicobacter pylori IgY,anti-helicobacter pylori enzyme(urease, proteases, lipase, phosph olipase)IgY,anti-E.coli(EHEC),anti-salmonella enteritidis IgY,anti-staphylococcus aureus IgY.
PL1687066T3 (en) * 2003-11-14 2013-01-31 Brigham & Womens Hospital Inc Methods of modulating immunity
ATE497782T1 (en) 2004-04-16 2011-02-15 Univ Alberta ANTI-GLUTEN EGG YOLK ANTIBODIES FOR TREATING ZOELIACIA
EP1723951A1 (en) * 2005-04-21 2006-11-22 N.V. Nutricia Nutritional supplement with oligosaccharides for a category of HIV patients
JP2007084495A (en) * 2005-09-22 2007-04-05 Daikin Ind Ltd Method for treating virus-infected cell
JP2007082486A (en) * 2005-09-22 2007-04-05 Daikin Ind Ltd Method for treating biologic material infected with virus, cell treated against infection virus, tissue treated against infection virus, organ treated against infection virus
CN101626784B (en) * 2006-08-31 2013-07-17 作为康可信托公司受托人的A.C.N.135493391股份有限公司 Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions
BRPI0716319A8 (en) 2006-10-25 2019-02-05 Aovatechnologies Inc method for reducing phosphate absorption in a human or non-human animal individual at risk of developing or developing hyperphosphatomy and method for reducing the side effects of vitamin d therapy in a human
US8282928B2 (en) 2007-05-30 2012-10-09 The Governors Of The University Of Alberta Anti-gluten egg yolk antibodies for the treatment of celiac disease
PE20141173A1 (en) 2010-11-23 2014-09-25 Pantheryx Inc COMPOSITIONS AND METHODS FOR TREATMENT IN WIDE-SPECTRUM CLINICAL APPLICATIONS, NON-DIFFERENTIATED OR COMBINED
US20130011410A1 (en) * 2011-07-07 2013-01-10 Amicus Biotech Inc. Egg White Antibodies for Prevention and Treatment of Specific Localized Intestinal Infections and Diseases Associated with a Pathogenic Organism or Molecule
US20140234337A1 (en) 2011-08-19 2014-08-21 Immortal Spirit Limited Antibody and antibody-containing composition
CN106749650B (en) * 2016-12-19 2021-06-25 姚善龙 Preparation method and application of composite IgY antibody for resisting cold virus, streptococcus pneumoniae and staphylococcus
KR102200721B1 (en) * 2019-11-18 2021-01-13 (주)애드바이오텍 Manufacturing method of immunoglobulin y for preventing or treating salmon rickettisia septicaemia
CN112957464A (en) * 2021-02-24 2021-06-15 江秀坤 Application of chicken egg yolk immunoglobulin in preparing throat-moistening health-care product

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19504755A1 (en) * 1995-02-02 1996-08-08 Panagiotis Tsolkas New antibodies against HIV antigens
US5585098A (en) * 1993-11-23 1996-12-17 Ovimmune, Inc. Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550019A (en) * 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
US4748018A (en) * 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
US5258178A (en) * 1990-07-30 1993-11-02 Abbott Laboratories Method and product for the treatment of gastric disease
US5420253A (en) * 1993-09-09 1995-05-30 Willmar Poultry Company, Inc. Method for purifying egg yolk immunoglobulins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585098A (en) * 1993-11-23 1996-12-17 Ovimmune, Inc. Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants
DE19504755A1 (en) * 1995-02-02 1996-08-08 Panagiotis Tsolkas New antibodies against HIV antigens

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FERTEL R ET AL: "Formation of antibodies to prostaglandins in the yolk of chicken eggs.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1981 OCT 15) 102 (3) 1028-33., XP000984898 *
See also references of WO9814209A1 *

Also Published As

Publication number Publication date
JP2001501622A (en) 2001-02-06
EP0930891A1 (en) 1999-07-28
KR20000048855A (en) 2000-07-25
NZ335170A (en) 2001-08-31
AU4741997A (en) 1998-04-24
WO1998014209A1 (en) 1998-04-09
AU729502B2 (en) 2001-02-01
CA2267421A1 (en) 1998-04-09

Similar Documents

Publication Publication Date Title
EP0930891A4 (en) Oral administration of chicken yolk antibodies to treat disease
GB9401520D0 (en) Treatment of poultry
PL335974A1 (en) Method of orally administering proteins
NO995134D0 (en) Improved Methods for Preparation of Activated Protein C
EP0979647A4 (en) Fat emulsion for oral administration
KR970000228A (en) Oral preparations of S-etodolak
ZA931489B (en) Use of interleuken-10 to suppress graft-vs-host disease
AU2340397A (en) Use of nicotine to treat liver disease
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
TR199701051A3 (en) Preparation process of 2 '-Fluoro-5-methyl--1-arabino-furanosyluridine
PL337064A1 (en) Method of and compositions for orally administering taxanes to human beings
IL117668A0 (en) Preparation of polyesters
IL115307A (en) Modification of egg composition by chicken feed supplements and the resulting eggs obtained
ZA969147B (en) Application of the gax protein to the treatment of cancer
ZA914435B (en) Treatment of disease
GB9801142D0 (en) Administration of beneficial substances to ruminant animals
HUP9801925A3 (en) Use of sodium-hydrogen-exchange-inhibitors for producing pharmaceutical compositions treating diseases caused by protozoons
AU7492087A (en) Newcastle disease virus protein
IL119282A0 (en) Treatment of fowl
ZA97210B (en) Oral administration of effective amunts of forms of hyaluronic acid
IL114923A0 (en) Chintin extract for treatment of skin disease
HU9702374D0 (en) Medical toothbrush for intake of effective substance
BR9503224A (en) Dual spray system to whiten teeth and dental prostheses
AU6100196A (en) Peptide analogs and their use as haptens to elicit catalytic antibodies
SI0777482T1 (en) Combined preparation for the therapy of immune diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990414

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010518

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020314

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030503